Source comparison
Human vs Animal Models: Why Extrapolation Is Complex
Rodent rotator cuff models use surgically induced acute tears in young, healthy animals with no prior degenerative changes. A scenario that rarely matches human pathology. Most human rotator cuff tears are chronic, occur in patients over 50, and involve pre-ex
This comparison does not assign a generated winner or score.
- Rodent rotator cuff models use surgically induced acute tears in young, healthy animals with no prior degenerative changes. A scenario that rarely matches human pathology. Most human rotator cuff tears are chronic, occur in patients over 50, and involve pre-existing tendinopathy, fatty infiltration, and muscle atrophy. The healing environment in a 55-year-old with a 6-month-old partial tear and concurrent glenohumeral arthritis is fundamentally different from a 12-week-old rat with an experimentally created acute injury.
- Dosing extrapolation is equally uncertain. Animal studies use 500–750 mcg per dose in 200–300g animals. That's roughly 2–3 mg/kg. Direct translation to a 70kg human would suggest 140–210 mg per dose, but subcutaneous bioavailability, half-life kinetics, and tissue distribution differ significantly between species. Anecdotal human protocols typically use 2–5 mg per dose, 2–3 times weekly. A fraction of the scaled animal dose. Whether this under-dosing explains lack of dramatic human outcomes or whether supra-physiological rodent doses simply don't translate is unknown.
- Our team has reviewed peptide literature across hundreds of compounds in this space. The pattern is consistent: animal efficacy often predicts human mechanism but rarely predicts human magnitude of effect. TB-500's biological plausibility is strong. The question isn't whether it does something, but whether what it does at achievable human doses justifies the cost, legal risk, and absence of long-term safety data.
- For researchers examining real peptides in controlled laboratory settings, purity and exact amino-acid sequencing matter more than in any other application category. Even minor sequence variations can alter receptor binding affinity and downstream signalling cascades.
- Rotator cuff recovery isn't a single intervention. It's a multi-month rehabilitation arc involving mechanical offloading, eccentric strengthening, sleep optimisation, and sometimes surgical repair. TB-500 studied torn rotator cuff research suggests the peptide can be one tool in that arc, but expecting it to function as monotherapy is inconsistent with the evidence base. The most rational approach combines TB-500 with structured physical therapy protocols that address scapular dyskinesis, posterior capsule tightness, and rotator cuff activation patterns. The biomechanical factors that caused the tear or prevent healing in the first place. A peptide that optimises cellular healing paired with biomechanics that continue tearing the tissue apart produces disappointing outcomes every time.